The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Knight Cancer Institute at Oregon Health and Science University launches statewide program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

THE KNIGHT CANCER INSTITUTE at Oregon Health & Science University launched a program to aid communities statewide in addressing cancer-related needs.

The institute made a decade-long commitment to invest $1 million annually through this program to assist groups that want to reduce the cancer burden in their communities.

Three tiers of grants are available to support a wide variety of projects: early stage grants provide up to $10,000, developmental grants offer up to $25,000 and program advancement grants supply up to $50,000. These grants will fund community-identified projects anywhere along the cancer continuum from prevention to early detection and treatment through survivorship.

Projects will be paired with an academic collaborator who will share best-practices, support program development and aid in evaluation measures. The information will be shared between organizations, academic collaborators, and the OHSU Knight Cancer Institute.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
By Claire Marie Porter and Paul Goldberg
Guest Editorial

How next generation sequencing is powering the shift to more accessible—and comprehensive—cancer care

Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more
By Kathy Davy
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account